Pragmatic Randomized Controlled Trial of Pharmacopuncture Therapy for Adhesive Capsulitis : A Pilot Study

Not Applicable

Completed

• Conditions: Adhesive Capsulitis
• Interventions: Procedure: pharmacopuncture therapy; Procedure: physical therapy

• Registration Number: NCT05292482
• Lead Sponsor: Jaseng Hospital of Korean Medicine

Brief Summary

This is a 2-arm parallel pragmatic randomized controlled trial that will compare pharmacopuncture therapy with physical therapy for adhesive capsulitis.

Detailed Description

Participants who voluntarily signed informed consent form and eligible for the study were randomly assigned in a 1:1 ratio (25:25) for pharmacopuncture therapy and physical therapy group. Participants of each group will receive twice a week for total 6 weeks of intervention. This is a pragmatic randomized controlled trial, so physicians will have medical decision making according to each participant's conditions.

Study Timeline

• Study First Submitted: 2022-03-15
• Study First Submitted QC: 2022-03-15
• Study First Posted: 2022-03-23
• Study Start: 2022-04-20
• Primary Completion: 2022-10-25
• Status Verified: 2022-12
• Study Completion: 2022-12-06
• Last Update Submitted: 2023-06-13
• Last Update Posted: 2023-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Limitation of the shoulder movement (active or passive)
• Numeric Rating Scale (NRS) of neck pain is more than 5
• Symptoms of adhesive capsulitis for more than 1 month
• Discrimination findings which can explain clinical symptoms on shoulder MRI or CT
• 19-69 years old
• participants who agreed and wrote informed consents

Exclusion Criteria

• Case of being diagnosed with a specific serious disease that may cause shoulder pain(Fracture, Dislocation, etc.)
• Cause of pain due to soft tissue disease, not the spine(Cancer, fibromyalgia, RA, goat, or etc.) Other chronic diseases(stroke, MI, kidney disease, diabetic neuropathy, dimentia, epilepsy, or etc.) that may interfere with the interpretation of therapeutic effects or outcomes
• Participants taking steroid, immunosuppressant, psychotropic medication, or taking other drugs that may affect outcomes
• Inappropriate or unsafe pharmacopuncture therapy; hemorrhagic disease, taking anticoagulant drug, or severe diabetes patients who are likely to be infected
• Participants who took NSAIDs or pharmacopuncture, acupuncture, physical therapy within 1 week
• Pregnant, planning to get pregnant or lactating women
• Participants who had undergone shoulder surgery within 3 months
• Participants who had participated in other clinical trial within 1 month, had participated in other study within 6 months from the date of selection, or have plan for participation in other trial during follow up period of this trial
• Participants who can not write informed consent
• Participants who is difficult to participate in the trial according to investigator's decision

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
pharmacopunture therapy	pharmacopuncture therapy	The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose.
physical therapy	physical therapy	The physicians will choose the type and time of physical therapy according to participants' conditions.

Primary Outcome Measures

Name	Time	Method
Numeric rating scale (NRS) of shoulder pain	week 7	NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.

Secondary Outcome Measures

Name	Time	Method
Visual analogue scale (VAS) of shoulder pain	week 1, 2, 3, 4, 5, 6, 7, 13	Visual analogue scale of shoulder pain, minimum 0 to maximum 100, which is a higher score means a worse outcome.
SPADI	week 1, 7, 13	SPADI is a functional disability questionnaire. The possible range of each item score is 0 to 10. Total score range is 0 (better outcome) to 100 (worse outcome).
SF-12 v2	week 1, 7, 13	The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.
EQ-5D-5L	week 1, 7, 13	The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about)
ROM(Range of motion)	week 1, 2, 3, 4, 5, 6, 7, 13	The range of shoulder movement shows the function of the shoulder capsule.
PGIC	week 7, 13	Participants rate the improvement after treatment on a 7-point Likert scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.)

Trial Locations

Locations (1)

Jaseng Korean Medicine Hospital; 🇰🇷 Seoul, Korea, Republic of